GDNF Splice Variant Pre-γ Pro-GDNF Neuronal Activity Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GDNF protein therapies for Parkinson's disease and other neurological disorders face challenges due to the lack of effective neuronal activity-dependent secretion mechanisms, leading to suboptimal therapeutic outcomes and safety concerns.
Innovation Solution
Identification and characterization of a novel GDNF splice variant, pre-(γ)pro-GDNF, which is secreted in a neuronal activity-dependent manner, offering a more potent therapeutic approach compared to traditional GDNF splice variants like pre-(α)pro-GDNF and pre-(β)pro-GDNF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional GDNF splice variants (pre-α)pro-GDNF and pre-(β)pro-GDNF) are used for therapy, then GDNF delivery is achieved, but neuronal activity-dependent secretion mechanism is lacking leading to suboptimal therapeutic outcomes
Solution Approach 1:
The invention changes the secretion parameter of GDNF from constitutive to neuronal activity-dependent by identifying and characterizing the pre-(γ)pro-GDNF splice variant. This variant contains a unique pro-region sequence that enables regulated secretion in response to neuronal activity, thereby improving therapeutic reliability while gaining adaptability to physiological conditions.
Solution Approach 2:
The invention segments the GDNF protein into different splice variants with distinct functional properties. The pre-(γ)pro-GDNF variant is separated from other variants through alternative splicing, creating a specific form that can be selectively expressed and secreted in a neuronal activity-dependent manner, resolving the contradiction between delivery efficiency and regulated secretion.
2Quantity of substance
If constitutive secretion of GDNF is used, then GDNF delivery is achieved, but safety concerns arise due to lack of regulated delivery
Solution Approach 1:
The invention transforms GDNF secretion from a static constitutive process to a dynamic regulated process. The pre-(γ)pro-GDNF variant responds to changing neuronal activity levels, allowing GDNF delivery quantity to dynamically adjust to physiological needs, thereby maintaining adequate delivery while reducing safety concerns associated with unregulated constitutive secretion.
3Adaptability or versatility
If pre-(γ)pro-GDNF is used for therapy, then neuronal activity-dependent secretion is achieved, but potential limitations of constitutive secretion variants remain
Solution Approach 1:
The pre-(γ)pro-GDNF variant implements a feedback mechanism where neuronal activity levels regulate GDNF secretion. The variant senses neuronal activity states and adjusts secretion accordingly, creating a self-regulating system that improves both adaptability to physiological conditions and reliability of therapeutic outcomes by preventing both under- and over-secretion.
Data Source
AI summary
The present invention relates to Glial Cell Line-Derived Neurotrophic Factor (GDNF) protein and gene and is, in particular, directed to a novel splice variant of GDNF protein, which is encoded by a novel splice variant pre-(γ)pro-GDNF, and secreted under biological regulation.